Indications for antifibrinolytic therapy.
D000614:Aminocaproates / Q000009:adverse effects / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D007611:Aprotinin / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000188:drug therapy; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy; D006417:Hematuria / Q000188:drug therapy; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy; D002836:Hemophilia B / Q000188:drug therapy; D006470:Hemorrhage / Q000188:drug therapy; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008595:Menorrhagia / Q000188:drug therapy; D011183:Postoperative Complications / Q000188:drug therapy; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy; D013923:Thromboembolism / Q000139:chemically induced; D014148:Tranexamic Acid / Q000627:therapeutic use
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid; D007611:Aprotinin